Crown Bioscience appoints Yangzhou Wang, PhD, one of the industry's preeminent operational scientists, as Senior VP of Global Operations.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research.
Yangzhou Wang has a PhD in Biological Sciences from the State University of New York at Buffalo. Dr Yangzhou Wang specialises in mergers and acquisitions, business integration and development.
As the VP of International Sales and Business Development at WuXi AppTec, he was the driving force behind the global growth of the company's preclinical and clinical testing businesses.
Dr Jean-Pierre Wery, CEO of CrownBio, said: "We are thrilled to bring Dr Wang onboard. CrownBio is experiencing tremendous, sustained growth, which has led to the expansion of eight offices worldwide. With our sustained success, Dr Wang's outstanding scientific expertise and international experience will further strengthen our global operational excellence."
Dr Wang also spent a significant part of his career in academia, including serving as the Manager at the Hewlett Packard Laboratories Advanced Studies Group and an assistant Professor at the Hauptman Woodward Medical Institute and the State University of New York at Buffalo.
Dr Wang, said: "I am very excited to join CrownBio. The impressive global reach and scientifically advanced preclinical oncology, cardiovascular and metabolic platform place it at the top of the industry, and make it the world's leading company for acceleration of drug discovery and development. I have long admired CrownBio's growth, innovation and scientific advancements and am looking forward to the extraordinary work we are going to create together."
CrownBio also announced the retirement of Dr Alex Wu and Bing Zhu from their positions as President/Chief Strategic Officer and COO.